TETRAPHASE PHARMACEUTICALS INC
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | |
|---|---|---|---|---|---|---|
| Revenue | $1.3M | $1.9M | $1.5M | $2.0M | $11.7M | $9.1M |
| Operating income | −$19.0M | −$21.9M | −$29.6M | −$16.8M | −$83.0M | −$65.8M |
| Net income | −$19.5M | −$21.6M | −$29.5M | −$16.7M | −$83.2M | −$66.7M |
| Total assets | $36.4M | $122.9M | $149.0M | $151.7M | $214.9M | $127.2M |
| Total liabilities | — | — | — | — | — | — |
| Equity | $23.2M | $79.7M | $130.4M | $140.1M | $204.1M | $108.6M |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | 53.7M | 51.6M | 37.1M | 36.6M | 31.0M | 25.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2019- Operating margin
- −1495.7%
- Net margin
- −1530.9%
- Return on equity
- −84.1%
- Return on assets
- −53.6%
- Return on capital (ROCE)
- −71.5%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $0.43
- Revenue growth (YoY)
- −32.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2019- Accruals / assets
- 121.4%high accruals
- Piotroski F-Score
- 1/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 5 warning● 0 good- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- High accruals — earnings-quality risk
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsJul 29, 2020
- Entered a material agreement · Terminated a material agreement · Other material eventJun 24, 2020
- Other material eventJun 22, 2020
- Other material eventJun 5, 2020
- Entered a material agreement · Terminated a material agreement · Other material eventJun 4, 2020
- Other material eventJun 1, 2020
- Entered a material agreement · Other material eventMay 29, 2020
- Other material eventMay 28, 2020
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.